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1271evaluated on a case-by-case basis and could be
considered in patients with left-to-right shunt and
evidence of progressive right ventricular or atrial
enlargement, right-sided chamber dysfunction, or
worsening pulmonary hypertension. Closure of iASD
in patients with persistent right-to-left shunt with
paradoxical embolus or arterial desaturation (hypox-
emia) might also be reasonable.*Jason H. Rogers, MD
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678–85.REPLY: Iatrogenic Atrial Septal Defect
After MitraClip TherapyWe thank Drs. Rogers and Smith for their comments
on our paper (1).
Drs. Rogers and Smith state that they were able to
publish data from the roll-in phase of the EVEREST
II (A Study of the Evalve Cardiovascular Valve Repair
[MitraClip] System Endovascular Valve Edge-to-Edge
Repair Study EVEREST II High Risk Registry) in 2012
reporting on markedly lower incidence rates of iat-
rogenic septal defect (iASD) after MitraClip use (27%)
(2). This group reported a correlation of detectable
iASD with cardiac remodeling (2), which was in part
conﬁrmed by our ﬁndings (1). Consequently, Drs.
Rogers and Smith question the novelty of our data.
Before we started our study program, we read their
paper with great interest and acknowledge this early
work. We want to point out that we did not deem
ourselves to be the ﬁrst group investigating inci-
dence rates of iASD after percutaneous mitral valve
repair. To the best of our knowledge we performed
the ﬁrst study in this ﬁeld “with serial TEE exami-
nations” (1).
Furthermore, several important differences be-
tween the 2 studies must be stressed, which makes a
head-to-head comparison impossible.First, Smith et al. (2) reported transthoracic echo-
cardiographic ﬁndings, which has important limita-
tions in this setting. Current guidelines deﬁne TEE
the gold standard for the evaluation of interatrial
shunt defects (3), and several studies were able to
show signiﬁcant differences in detectable iASD rates
if determined with transthoracic echocardiographic
ﬁndings or transesophageal echocardiography (TEE)
(4). Second, the main focus of our research was to
evaluate the correlation of iASD persistence with the
treated patients’ clinical outcomes, which was not
addressed by Smith et al. (2).
Third, we included nonsurgical, highest-risk pa-
tients, including 73% of subjects with functional
mitral valve regurgitation, which is in contrast to
Smith et al. (2) reporting on degenerative valve
disease in patients suitable for MV replacement.
The persistence rate of iASD and its clinical con-
sequences might differ relevantly between high-risk
heart failure patients and the early EVEREST II
population (5). As we discussed in our paper (1),
we agree with Smith and Rogers that the “true”
signiﬁcance of iASD after percutaneous mitral valve
repair remains unknown. Our results— in context
with available data—showed a noticeable correla-
tion of iASD persistence with patients’ functional
outcomes and survival. As we clearly stated (1), the
underlying pathomechanisms for iASD persistence
are not fully understood, and we emphasize the
need for prospective trials addressing this topic.
Currently, interventional closure of an iASD after
percutaneous mitral valve repair must be planned
based on a careful, individual case-by-case
decision.Robert Schueler, MD
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364:1395–406.True Fractional Flow
Reserve of Left Main
Coronary Artery Stenosis
in the Presence of
Downstream Coronary
StenosesWith great interest I read the recent paper by
Fearon et al. (1) in which they assessed the impact of
downstream left anterior descending (LAD) or left
circumﬂex (LCX) coronary stenosis on the assessment
of fractional ﬂow reserve (FFR) of an left main coro-
nary artery (LMCA) stenosis. They concluded that if
the apparent FFR of the LMCA (FFRapp) is >0.85, the
true FFR of the LMCA (FFRtrue) is always >0.80. If
FFRapp is between 0.81 and 0.85 and the epicardial
FFR (FFRepi) is &0.45, then FFRtrue is &0.80 in some
cases.
However, these conclusions are not surprising.
These conclusions can be proven mathematically.
Bruyne et al. (2) previously described theoretical
equations that calculate the true FFR of individual
stenosis in a tandem lesion. Based on their study, an
equation that calculates FFRtrue in a bifurcation
lesion can be derived. When the downstream steno-
sis is located in the LAD, and n is deﬁned as the ratio
of microcirculatory resistances of the LCX to the
LAD, FFRtrue is calculated as per the following
Equation 1.
FFRtrue ¼
nFFRepi þ FFRapp
1þ n1 FFRapp  FFRepi
 (1)
The partial differentiation of FFRtrue with respect to
FFRepi is calculated as follows:
vFFRtrue
vFFRepi
¼ nðnþ 1Þ

1 FFRapp

1þ n1 FFRapp  FFRepi
2>0 (2)The above inequality in Equation 2 indicates that
the FFRtrue monotonically increases when FFRepi is
larger. Similarly, the partial differentiation of
FFRtrue with respect to FFRapp and n are calculated
as follows:
vFFRtrue
vFFRapp
¼ ðnþ 1Þ

nFFRepi þ 1

1þ n1 FFRapp  FFRepi
2>0 (3)
vFFRtrue
vn
¼

1 FFRapp

FFRepi  FFRapp

1þ n1 FFRapp  FFRe
2 < 0 (4)
The inequalities in Equations 2, 3, and 4 suggest
that FFRtrue increases with FFRepi and FFRapp, but
that it decreases with an increase in n. n is the ratio
of microcirculatory resistances of the LCX to the
LAD, which is usually considered approximately 2.
Thus, FFRtrue > 080 is always true when FFRapp is
>0.85, FFRepi is >0.45, and n ¼ 2. Similarly, Equation 1
suggests that when FFRapp is between 0.81 and 0.85
and the epicardial FFR (FFRepi) is&0.45, then FFRtrue
can be either larger or smaller than 0.80. These cal-
culations are completely in accordance with the
study results of Fearon et al. (1). Their study was well
designed and the results were reasonable, but it
lacked the understandings of the background mech-
anism. Another important limitation of their study is
that they only assessed the LMCA plus 1 downstream
stenosis and lacked the assessment of the LMCA plus
2 downstream stenoses both in the LAD and LCX,
which is also frequently encountered in clinical
practice. In the case of the LMCA plus 2 downstream
stenoses, FFRtrue is calculated as per Equation 5 when
the epicardial FFR of the LAD and LCX are deﬁned as
FFRLAD and FFRLCX.
FFRtrue ¼
nFFRLAD þFFRLCX
1 FFRapp FFRLCX
þn1FFRapp FFRLAD

(5)
I hope that the legitimacy of Equation 5 will be
assessed in the future clinical study.*Naritatsu Saito, MD
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